

Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Lawrence B. Bugaisky Michael V. Messinger Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Alber L. Fenov
Ponald R. Banov
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Vincent L. Capuano
Vincent L. Capuano
Circipi Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lbulier
Rea Lynn P. Guest

George S. Bardmesser Daniel A. Klein Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Aric W. Ledford Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle' Gaby L. Longsworth Lori A. Gordon Nicole D. Dretar Ted J. Ebersole Jyoti C. Iyer Laura A. Vogel Michael J. Mancuso Bryan S. Wade Aaron L. Schwartz Michael G. Penn* Shannon A. Carroll* Wesley W. Jones* Matthew E. Kelley* Nicole R. Kramer*

Registered Patent Agents Karen R. Markowicz Nancy J. Leith Matthew J. Dowd Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford Michelle K. Holoubek Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse Christopher J. Walsh Liliana Di Nola-Baron Peter A. Socarras Jeffrey Mills

AF IIW

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

May 16, 2005

WRITER'S DIRECT NUMBER: (202) 772-8762 INTERNET ADDRESS: NLBITH@SKGF.COM

Mail Stop: AF

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 09/830,964; § 371 Date: November 5, 2001

For: Methods of Purifying Recombinant Human Erythropoietin from Cell

Culture Supernatants

Inventors: C

Carcagno et al.

Our Ref:

1909.0030002/PAJ/NJL

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Amendment and Reply Under 37 C.F.R. § 1.116; and
- 2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents May 16, 2005 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Nancy J. Leth

Nancy J. Leith Agent for Applicants Registration No. 45,309

PAJ/NJL:cpn Enclosures

398917_1.DOC

Sterne, Kessler, Goldstein & Fox PLL.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com



Amendment Under 37 C.F.R. § 1.116 Expedited Procedure – Art Unit 1654

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Carcagno et al.

Appl. No.: 09/830,964

§ 371 Date: November 5, 2001

For: Methods of Purifying Recombinant Human Erythropoietin from Cell

Culture Supernatants

Confirmation No.: 5291

Art Unit: 1654

Examiner: Tate, Christopher Robin

Atty. Docket: 1909.0030002/PAJ/NJL

Amendment and Reply Under 37 C.F.R. § 1.116

Mail Stop AF

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated February 24, 2005, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims; and
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent

abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.